The G-Rex Grant is part of ScaleReady’s USD 20 million programme aimed at advancing Cell and Gene Therapy (CGT) development and manufacturing. With this funding, Neogap Therapeutics will optimise manufacturing for pTTL (personalised Tumour Trained Lymphocytes), an ATMP (Advanced Therapy Medicinal Product) that combines EpiTCer^® technology with the PIOR^® AI platform.

Designed to target neoantigens with precision, pTTL uses the patient’s immune cells to generate tumour-specific T cells. It is currently being evaluated in a Phase I/IIa clinical trial in patients with advanced colorectal cancer.

“We are very excited to have been selected for this significant grant from ScaleReady and look forward to incorporating the G-Rex platform into our pTTL manufacturing process,” says Kristine Bylund, Head of Cell Therapy Production and Development at Neogap Therapeutics. “Our development team has already completed preliminary experiments, and this grant will allow us to continue the development of a robust and cost-effective bioreactor process required to meet our quality and safety standards for clinical production, bringing us closer to our goal of delivering personalised medicine to patients in need.”

“We are fortunate to have the opportunity to help Neogap develop a cost-effective G-Rex^® centric manufacturing process to create personalised Tumour Trained Lymphocytes. Neogap’s novel approach has the potential to make a highly favorable impact on clinical outcomes for patients with advanced colorectal cancer and are grateful for the opportunity to participate,” says John Wilson, CEO of Wilson Wolf and co-inventor of G-Rex. 

About Neogap’s immunotherapy, pTTL
pTTL (personalised Tumour Trained Lymphocytes) is a cell-based immunotherapy that enhances the patient’s own T cells to fight cancer. The therapy combines advanced DNA analysis with T-cell expansion in a precision treatment for solid tumours. It is based on Neogap’s patented technologies, PIOR^® and EpiTCer^®. The goal is to provide patients with a tailored and innovative therapy that meets their specific needs.

Project reference number: 190185439 – NEOpTTL. Funded by the European Union. Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the European Union or EISMEA. Neither the European Union nor the granting authority can be held responsible for them.

For more information, please contact:
Samuel Svensson, CEO
Email: samuel.svensson@neogap.se
Phone: +46 733 54 21 94

About Neogap Therapeutics
Neogap Therapeutics is a Swedish clinical-stage biotechnology company focused on developing personalised cancer immunotherapy using the patient’s own cells. The therapy is based on the company’s two technologies PIOR^® and EpiTCer^®. PIOR^® is sophisticated software that uses DNA sequencing data from the patient and machine learning algorithms to select tumour-specific mutations. Then, EpiTCer^® is used to multiply T cells that can recognize and attack the selected tumor-specific targets. Neogap is located at Cancer Center Karolinska in Stockholm. To learn more about Neogap and its cutting-edge research, please visit the company’s website at neogap.se and follow Neogap on LinkedIn.

About ScaleReady™
ScaleReady provides the field of cell and gene-modified cell therapy (CGT) with a G-Rex-centric manufacturing platform that enables practical, flexible, scalable, and affordable CGT drug product development and manufacturing. The G-Rex manufacturing platform is currently used by over 800 organizations and is producing drug products for approximately 50% of CGT clinical trials as well as 4 commercially approved CGT drugs. For more information about the ScaleReady G-Rex^® Grant Program, please contact info@scaleready.com.

About Wilson Wolf Manufacturing Corporation
Wilson Wolf is dedicated to simplifying cell and gene-modified cell (CGT) therapy research, process development, and clinical and commercial manufacturing through its scalable G-Rex^® technology. For more information, please visit https://www.wilsonwolf.com/.